Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (review)

International Journal of Molecular Medicine

Volumn 3, Issue 5, 1999, Pages 511-515

  Herouy, Yared ^a   Nockowski, Piotr ^a   Schöpf, Erwin ^a   Norgauer, Johannes ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Matrix metalloproteinases; Plasminogcn activation; Venous ulcers

Indexed keywords

MESSENGER RNA; METALLOPROTEINASE; PLASMINOGEN; PROTEINASE;

EXTRACELLULAR MATRIX; FIBRINOLYSIS; GENETICS; HUMAN; LOCALIZED SCLERODERMA; METABOLISM; REVIEW; VARICOSIS;

ENDOPEPTIDASES; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMANS; METALLOENDOPEPTIDASES; PLASMINOGEN; RNA, MESSENGER; SCLERODERMA, LOCALIZED; VARICOSE ULCER;

EID: 0033127460     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.3.5.511     Document Type: Article

References (25)

1. Huricz C, Lcgache G and Desmons F: Ulceres de jambes et troubles trophiques d' origine veineuse (donnes tirees de l' etude d' un millier d' ulcereux hospitalises). Rev Pract 5: 2703-2721, 1955.
2. Jorrizo JL, White WL and Zanolli MD: Sclerosing panniculitis. Arch Dcrmatol 115: 449-452, 1991.
3. Naschitz JE, Boss JH, Misselevich I, Yeshurun D and Rosner I: The fasciitis-panniculitis syndromes. Clinical and pathologie features. Medicine 75: 6-16, 1996.
4. Brinckmann J, Acil Y, Tronnicr M, Notbohm H, Bätge B, Schmellcr W, Koch MHJ, Müller PK and Wolff H: Altered x-ray difraction pattern is accompanied by a change in the mode of cross-link formation in lipodermtosclerosis. J Invest Dcrmatol 107:589-592,1996.
5. Greenberg AS, Hasan A, Montalvo BM, Falabella A and Falanga V: Acute lipodermatosclcrosis is associated with venous insufficiency. J Am Acad Dermatol 35: 566-568, 1996.
6. Kirsncr RS, Pardes JB, Eaglstcin WH and Falanga V: The clinical spectrum of lipodcrmatosclerosis. J Am Acad Dcrmatol 28: 623-627, 1993.
7. Ncmcth AJ, Eaglcstcin WH and Falanga V: Clinical parameters and transcutancous oxygen measurements for the prognosis of venous ulcers. J Am Acad Dcrmatol 20: 186-190, 19897
8. Herrick SE, Sloan P, McGurk M, Freak L, McCollum CN and Ferguson MWJ: Sequential changes in histologie pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am JTathol 141: 1085-1095, 1992.
9. Weckroth M, Vaheri A, Lauharanta J, Sorsa T and Konttincn YT: Matrix metalloproteinases, gelatinase and collagenase in chronic leg ulcers. J Invest Dermatol 106: 1119-1124,1996.
10. Wysocki AB, Staiano-Coico L and Grinnell F: Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dcrmatol 101: 64-68, 1993.
11. Vaalomo M, Manila L, Johansson N, Kariniemi AL, Karjalainen-Lindsbcrg ML, Kahari VM and Saarialho-Kcre U: Distinct populations of stromal cells express collagenasc-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dcrmatol 109: 96-101, 1997.
12. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodclintg. FASEB J 5: 2145-2154, 1991.
13. Birkcdal-Hansen H: Proteolytic remodeling of extracellular matrix. CurrOpinCell Biol 7: 728-735, 1995.
14. Shapiro SD: Matrix metalloproteinasc degradation of extra-cellular matrix: biological consequences. Curr Opin Cell Biol 10: 602-608, 1998.
15. Powell WC and Matrisan LM: Complex roles of matrix metalloproteinases in tumor progression. Attempts to understand metastasis formation. In: Metastasis Related Molecules. Gunther U, Schlag PM and Birchmeicr W (cds). Springer-Verlas, Heidelberg, pp 1-21, 1996. . - .
16. Howard EW, Bullen EC and Banda MJ: Preferential inhibition of 72- and 92-kDa celatinases by tissue inhibitors of mctalloprotcinasc-2. J Biol Chem 266: 13070-13075,1991.
17. Mazzieri R, Masicro L, Zanctta L, Monca S, Onisto M, Barbisa S and Mignatti P: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound rcactants. EMBO J-16: 2319-2332, 1997.
18. Browse NL, Gray L, Jarrett PE and Morland M: Blood and vcinwall fibrinolytic activity in health and vascular disease. Br McdJ 1:478-481, 1977.
19. Wolfe JHN, Morland M and Browse NL: The fibrinolytic activity of varicose veins. BrJSurg 66: 185-187, 1979.
20. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogcn activators, tissue deeradation, and cancer (review). Adv Cancer Res 44: 139-266, 1985.
21. Vassalli JD, Sappino AP and Belin D: The plasminogen activator/ plasmin system (review). J Clin Invest 88: 1067-1072, 1991.
22. Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Rømer J, Danø K, Carmeliet P, Collen D and Degen JL: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sei USA 93: 5899-5904, 1996.
23. Stahl A and Mueller B: Binding of urokinasc to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54: 3066-3071, 1994.
24. Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT, Schöpf E, Norgauer J and Vanscheidt W: Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases. Implications for venous ulcer formation. J Invest Dermatol 111: 822-827, 1998.
25. Jarret PE, Burnand KG, Morland M and Browse NL: Proceedings: fibrinolysis and fat necrosis in the lower leg. Br J Surg 63: 157-160, 1976.